Albireo Pharma Inc

Company Profile

Albireo Pharma Inc had its IPO on 2007-05-11 under the ticker symbol ALBO.

The company operates in the Healthcare sector and Biotechnology industry. Albireo Pharma Inc has a staff strength of 130 employees.

Stock update

Shares of Albireo Pharma Inc opened at $44.9 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $43.99 - $44.9, and closed at $44.15.

This is a -0.23% slip from the previous day's closing price.

A total volume of 1,260,806 shares were traded at the close of the day’s session.

In the last one week, shares of Albireo Pharma Inc have increased by +1.49%.

Albireo Pharma Inc's Key Ratios

Albireo Pharma Inc has a market cap of $915.89 million, indicating a price to book ratio of 4.3049 and a price to sales ratio of 7.3476.

In the last 12-months Albireo Pharma Inc’s revenue was $57.39 million with a gross profit of $39.22 million and an EBITDA of $-122812000. The EBITDA ratio measures Albireo Pharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Albireo Pharma Inc’s operating margin was -214.74% while its return on assets stood at -24.94% with a return of equity of -93.08%.

In Q3, Albireo Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 168.3%.

Albireo Pharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-6.66 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Albireo Pharma Inc’s profitability.

Albireo Pharma Inc stock is trading at a EV to sales ratio of 4.53 and a EV to EBITDA ratio of -2.112. Its price to sales ratio in the trailing 12-months stood at 7.3476.

Albireo Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$321.22 million

Total Liabilities

$37.82 million

Operating Cash Flow

$-40000.00

Capital Expenditure

$960000

Dividend Payout Ratio

0%

Albireo Pharma Inc ended 2023 with $321.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $321.22 million while shareholder equity stood at $100.07 million.

Albireo Pharma Inc ended 2023 with $0 in deferred long-term liabilities, $37.82 million in other current liabilities, 207000.00 in common stock, $-421033000.00 in retained earnings and $17.26 million in goodwill. Its cash balance stood at $222.48 million and cash and short-term investments were $222.48 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Albireo Pharma Inc’s total current assets stands at $238.84 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.03 million compared to accounts payable of $6.95 million and inventory worth $3.15 million.

In 2023, Albireo Pharma Inc's operating cash flow was $-40000.00 while its capital expenditure stood at $960000.

Comparatively, Albireo Pharma Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$44.15

52-Week High

$45.23

52-Week Low

$16.02

Analyst Target Price

$43.8

Albireo Pharma Inc stock is currently trading at $44.15 per share. It touched a 52-week high of $45.23 and a 52-week low of $45.23. Analysts tracking the stock have a 12-month average target price of $43.8.

Its 50-day moving average was $37.97 and 200-day moving average was $25.15 The short ratio stood at 1.38 indicating a short percent outstanding of 0%.

Around 361% of the company’s stock are held by insiders while 10768.9% are held by institutions.